Evaluation Of Correlation Between Hormone Receptor Status And Her2 Expression In Breast Cancer

Breast cancer as the most common malignancy in women and the leading cause of cancer-related death has been scrutinized for hormone receptor assay and cytogenetic markers analysis in the past two decades. Estrogen/progesterone receptor status and Her oncogene expression are among the most extensively studied markers with significant impact on prognosis.In the present preliminary study results of hormone receptor assay and Her expression analysis have been evaluated in a population of patients with newly diagnosed primary breast carcinoma in two university hospitals during a five-year period.SUBJECTS AND METHODS:Results of Histopathological examination, Immunohistochemical analysis and Cytogenetic assays were collected from the files of Breast cancer Registry and recorded in statistical analysis.Intensity of staining for immunohistochemical markers were reported according to the extent and number of cells showing positive reactivity. Her2 expressions were detected by immunohistochemical method. In ten patients Her2 oncogene were detected by fluorescent in situ hybridization in cytogenetic laboratory.RESULTS:Among 360 patinets enrolled in the present study 315 had Ductal carcinoma and 45 had mixed ductal and lobular histological appearance.Tissue Specimen from 180 patients revealed strongly positive staining for both Estrogen/Progestron receptors. Another one hundred and twenty specimens were negative for ER/PR but positive for Her2 receptor expression. This letter reactivity was more frequent in premenopausal women with primary breast carcinoma.Sixty cases showed neither hormone receptor expression nor Her2 oncogene overexpression.CONCLUSION:*Hormone Receptor positive Breast carcinoma may have frequently decreased Her2 oncogene expression. *Hormone Receptor negative primary Breast Cancer have somewhat increased probability of Her2 positive reactivity particularly in premenopausal women with adjacent axillary lymph node involvement.*Simultaneous HR negative and Her2 negative primary breast tumor encountered in a small proportion of patients may have a different histogenesis Myoepithelial *Can the Immunohistochemical assay be replaced by FISH or Elisa for Her2 detection